Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus
-
- Shunichiro Tsukamoto
- Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan
-
- Shohei Tanaka
- Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan
-
- Takayuki Yamada
- Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan
-
- Kazushi Uneda
- Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan
-
- Kengo Azushima
- Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan
-
- Sho Kinguchi
- Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan
-
- Hiromichi Wakui
- Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan
-
- Kouichi Tamura
- Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>To compare the therapeutic effects of glucose‐dependent insulinotropic polypeptide (GIP)/ glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) or GLP‐1RAs in Japanese patients with type 2 diabetes (T2D).</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods</jats:title><jats:p>We systematically searched PubMed, MEDLINE, EMBASE, and the Cochrane Library up to July 2023. Randomized controlled trials (RCTs) that compared GLP‐1RAs or GIP/GLP‐1RAs in Japanese patients with T2D were selected. A network meta‐analysis was conducted to indirectly compare the treatments, focusing on efficacy in reducing glycated haemoglobin (HbA1c) levels and body weight (BW).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 18 RCTs were included in this analysis. Tirzepatide 15 mg showed the most significant reduction in HbA1c levels and BW compared with subcutaneous semaglutide 1.0 mg and oral semaglutide 14 mg (HbA1c: mean difference [95% confidence interval] −0.52 [−0.96; −0.08] and − 1.23 [−1.64; −0.81]; BW: −5.07 [−8.28; −1.86] and −6.84 [−8.97; −4.71], respectively). Subcutaneous semaglutide showed a superior reduction in HbA1c compared with oral semaglutide. Both subcutaneous and oral semaglutide were more effective than conventional GLP‐1RAs, such as dulaglutide, liraglutide and lixisenatide.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Among Japanese patients with T2D, tirzepatide showed the greatest effectiveness in reducing HbA1c levels and inducing weight loss. The study provides evidence to guide GLP‐1RA treatment strategies in Japanese patients with T2D.</jats:p></jats:sec>
収録刊行物
-
- Diabetes, Obesity and Metabolism
-
Diabetes, Obesity and Metabolism 26 (1), 262-274, 2023-10-12
Wiley